DIFFERENTIATED MECHANISM FOR TREATMENT OF INFLAMMATION

There is no treatment specifically targeting monocytes, key immune cells controlling the inflammatory response. Several drugs target and inhibit T cell or B cell mediated immune response, but the inflammation persists.

IW-601 is an antibody that specifically targets MOSPD2, a newly discovered adhesion checkpoint. By binding MOSPD2 on the cell surface, IW-601 locks monocytes in a `sticky` state, blocking them from reaching the inflammatory tissue.